CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
FAM168B 被鉴定为基于 CAR-T 细胞的癌症治疗新型候选靶点
英文原题：FAM168B identified as a novel candidate target for chimeric antigen receptor T cell-based cancer therapy.
查看英文原题
FAM168B identified as a novel candidate target for chimeric antigen receptor T cell-based cancer therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
与衰老相关的疾病，尤其是癌症，仍是重大健康挑战，需要新的治疗策略。嵌合抗原受体（CAR）T细胞疗法已成为肿瘤免疫学中的强效治疗方式，可在体外工程化改造患者来源T细胞，使其识别并清除肿瘤抗原。本研究鉴定FAM168B（序列相似家族168成员B，又称髓鞘相关神经突起生长抑制因子MANI）及其同源蛋白FAM168A（舌癌耐药相关蛋白1，TCRP1）为候选膜相关蛋白，表达于癌细胞表面。FAM168B的独特特征提示其可能成为CAR-T 细胞开发的肿瘤特异性靶点。该方法可扩展CAR-T 疗法的治疗靶点库，并支持为多种癌症设计更加精准、适用范围更广的治疗策略。
展开英文摘要原文
Aging-related diseases, particularly cancer, remain major health challenges that demand new therapeutic strategies. Chimeric antigen receptor (CAR) T cell therapy has emerged as a powerful modality in immuno-oncology, enabling patient-derived T cells to be engineered ex vivo to recognize and eliminate tumor antigens.
Here, we identify FAM168B (family with sequence similarity 168 member B, also known as myelin-associated neurite-outgrowth inhibitor, MANI) and its homolog FAM168A (tongue cancer resistance-associated protein 1, TCRP1) as candidate membrane-associated proteins expressed on cancer cell surfaces.
The unique characteristics of FAM168B suggest its potential as a tumor-specific target for CAR T cell development. This approach could expand the therapeutic repertoire of CAR T cell therapy and support the design of more precise and versatile treatment strategies for diverse cancer types.
论文信息
- 作者
- Pramanik S、Thaker M、Inoue N、Kim PS、Kutzner A、Manavalan A、Pramanik G、Heese K
- 第一作者单位
- Jyoti and Bhupat Mehta School of Health Sciences and Technology, Center for Nanotechnology, Indian Institute of Technology Guwahati, Guwahati, 781039, Assam, India. subrata.pramanik@iitg.ac.in.India
- 通讯作者单位
- Graduate School of Biomedical Science and Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul, 04763, Republic of Korea. klaus@hanyang.ac.kr.South Korea
- 文献类型
- 综述
- 期刊
- Discover oncology2026 Jan 27
- 原文标识
- PubMed 41591662 · DOI 10.1007/s12672-025-03876-3
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →